The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for ...
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback